LIVIVO - Search results -

Search results

Result 1 - 8 of total 8

Search options

Article: A case report of extramedullary plasmocytoma-rare pathology in the larynx.

van Lanschot, Cornelia G F / Böhmer, Lara H / Ten Berge, Rosita L / Vinke, Jeroen G

2023 Volume 11, Issue 9, Page(s) e7884

Abstract: Extramedullary plasmocytoma is a rare finding. The diagnosis is made by histological and immunohistochemical examination. Hematological evaluation is mandatory to rule out multiple myeloma. Radiotherapy is treatment of choice with good results. ...

Abstract	Extramedullary plasmocytoma is a rare finding. The diagnosis is made by histological and immunohistochemical examination. Hematological evaluation is mandatory to rule out multiple myeloma. Radiotherapy is treatment of choice with good results.
Language	English
Publishing date	2023-09-15
Publishing country	England
Document type	Case Reports
ZDB-ID	2740234-4
ISSN	2050-0904
ISSN	2050-0904
DOI	10.1002/ccr3.7884
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Synchronous diffuse large B-cell lymphoma and mantle cell lymphoma: support for low-threshold biopsies and genetic testing.

de Groot, Fleur A / de Haan, Lorraine M / de Groen, Ruben A L / Heijmen, Linda / van Wezel, Tom / van Eijk, Ronald / Bohmer, Lara / Bot, Freek / Ten Berge, Rosita L / Diepstra, Arjan / Veelken, Hendrik / Cleven, Arjen H G / Jansen, Patty M / Vermaat, Joost S P

Leukemia & lymphoma

2021 Volume 63, Issue 5, Page(s) 1251–1255

MeSH term(s)	Adult ; Biopsy ; Genetic Testing ; Humans ; Lymphoma, Follicular/pathology ; Lymphoma, Large B-Cell, Diffuse/diagnosis ; Lymphoma, Large B-Cell, Diffuse/genetics ; Lymphoma, Large B-Cell, Diffuse/pathology ; Lymphoma, Mantle-Cell/diagnosis ; Lymphoma, Mantle-Cell/genetics ; Lymphoma, Mantle-Cell/pathology
Language	English
Publishing date	2021-12-21
Publishing country	United States
Document type	Letter
ZDB-ID	1042374-6
ISSN	1029-2403 ; 1042-8194
ISSN (online)	1029-2403
ISSN	1042-8194
DOI	10.1080/10428194.2021.2015589
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2997: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Pyoderma gangrenosum na mammachirurgie.

Haenen, Caroline C P / ten Berge, Rosita L / Posch, Nicole A S / Braam, Marjorie J I

Nederlands tijdschrift voor geneeskunde

2012 Volume 156, Issue 41, Page(s) A4984

Abstract: Pyoderma gangrenosum is a rare, destructive ulcerative condition of the skin. The painful ulcers may occur spontaneously, or result from a minor injury or surgery. The clinical presentation can mimic a necrotizing bacterial infection; however, no micro- ... ...

Title translation	Pyoderma gangrenosum following breast surgery.
Abstract	Pyoderma gangrenosum is a rare, destructive ulcerative condition of the skin. The painful ulcers may occur spontaneously, or result from a minor injury or surgery. The clinical presentation can mimic a necrotizing bacterial infection; however, no micro-organisms can be cultured from the skin lesions and the ulcers fail to respond to antibiotic therapy. Surgical interventions can aggravate the disease process. We describe 2 patients, a 22-year-old woman and a 45-year-old woman, with ulcerative wound abnormalities after breast surgery. After failure of antibiotic therapy and standard wound care, tissue biopsy of the wounds confirmed the clinical diagnosis 'pyoderma gangrenosum'. Wound healing began after systemic steroid treatment. Delays in diagnosis and treatment of pyoderma gangrenosum may result in extensive ulceration and scarring. It is, therefore, important to recognise the characteristic clinical features at an early stage and to start appropriate treatment immediately.
MeSH term(s)	Breast/pathology ; Breast/surgery ; Female ; Humans ; Immunosuppressive Agents/therapeutic use ; Mammaplasty/adverse effects ; Middle Aged ; Pyoderma Gangrenosum/drug therapy ; Pyoderma Gangrenosum/etiology ; Surgical Wound Infection/complications ; Treatment Outcome ; Young Adult
Chemical Substances	Immunosuppressive Agents
Language	Dutch
Publishing date	2012
Publishing country	Netherlands
Document type	Case Reports ; English Abstract ; Journal Article ; Review
ZDB-ID	82073-8
ISSN	1876-8784 ; 0028-2162
ISSN (online)	1876-8784
ISSN	0028-2162
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.18: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects--a review.

ten Berge, Rosita L / Oudejans, Joost J / Ossenkoppele, Gert J / Meijer, Chris J L M

The Journal of pathology

2003 Volume 200, Issue 1, Page(s) 4–15

Abstract: Anaplastic large cell lymphoma (ALCL) can be divided into two major groups. The first is a spectrum of CD30+ T-cell lymphoproliferative disorders including primary cutaneous ALCL and lymphomatoid papulosis, usually affecting older patients but ... ...

Abstract	Anaplastic large cell lymphoma (ALCL) can be divided into two major groups. The first is a spectrum of CD30+ T-cell lymphoproliferative disorders including primary cutaneous ALCL and lymphomatoid papulosis, usually affecting older patients but characterized by an excellent prognosis. The second is systemic nodal ALCL, which on the basis of genetic and immunophenotypic features combined with clinical parameters can be divided into two subgroups: anaplastic lymphoma kinase (ALK)-positive and ALK-negative systemic ALCL. ALK expression, usually the result of a t(2;5) translocation, correlates with the expression of other markers such as EMA and a cytotoxic phenotype, and is strongly related to younger age groups, lower international prognostic index (IPI) risk groups, and a good prognosis. ALK-negative ALCL, however, shows a more heterogeneous immunophenotype and clinical behaviour, and prognostic parameters are needed to determine treatment strategies in individual patients. Besides clinical parameters included in the IPI, recent studies have pointed out several biological prognosticators of potential value, such as the percentage of tumour-infiltrating activated cytotoxic T-lymphocytes. The expression of proteins involved in the execution or regulation of apoptosis, such as activated caspase 3, Bcl-2, and PI9, was also found to be strongly related to clinical outcome. These studies indicate that inhibition of the apoptosis cascade in particular is an important mechanism that can explain the poor clinical outcome in therapy refractory ALCL. Functional studies are required to investigate whether disruption of one or more of the apoptosis pathways is the major factor in the fatal outcome of the disease and whether apoptosis resistance based on inhibition of one pathway can be overcome by activating another pathway that is still intact.
MeSH term(s)	Apoptosis/physiology ; Caspase 3 ; Caspases/metabolism ; Diagnosis, Differential ; Humans ; Immunophenotyping ; Ki-1 Antigen/analysis ; Lymphoma, Large-Cell, Anaplastic/diagnosis ; Lymphoma, Large-Cell, Anaplastic/drug therapy ; Lymphoma, Large-Cell, Anaplastic/enzymology ; Lymphoproliferative Disorders/pathology ; Models, Biological ; Neoplasm Proteins/analysis ; Prognosis ; Protein-Tyrosine Kinases/analysis ; Protein-Tyrosine Kinases/metabolism ; Proto-Oncogene Proteins c-bcl-2/analysis ; Receptor Protein-Tyrosine Kinases ; Serpins/analysis ; Skin Neoplasms/diagnosis ; Skin Neoplasms/pathology ; T-Lymphocytes ; T-Lymphocytes, Cytotoxic/pathology
Chemical Substances	Ki-1 Antigen ; Neoplasm Proteins ; Proto-Oncogene Proteins c-bcl-2 ; SERPINB9 protein, human ; Serpins ; Protein-Tyrosine Kinases (EC 2.7.10.1) ; Receptor Protein-Tyrosine Kinases (EC 2.7.10.1) ; anaplastic lymphoma kinase (EC 2.7.10.1) ; CASP3 protein, human (EC 3.4.22.-) ; Caspase 3 (EC 3.4.22.-) ; Caspases (EC 3.4.22.-)
Language	English
Publishing date	2003-05
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	3119-7
ISSN	1096-9896 ; 0022-3417
ISSN (online)	1096-9896
ISSN	0022-3417
DOI	10.1002/path.1331
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ud II Zs.12: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Apoptosis in B-cell lymphomas and reactive lymphoid tissues always involves activation of caspase 3 as determined by a new in situ detection method.

Dukers, Danny F / Oudejans, Joost J / Vos, Wim / ten Berge, Rosita L / Meijer, Chris J L M

The Journal of pathology

2002 Volume 196, Issue 3, Page(s) 307–315

Abstract: In vitro studies indicate that in lymphomas, execution of apoptosis involves activation of effector caspases. To investigate activation of effector caspases in vivo in biopsy specimens of lymphomas, a new assay was developed using antibodies against ... ...

Abstract	In vitro studies indicate that in lymphomas, execution of apoptosis involves activation of effector caspases. To investigate activation of effector caspases in vivo in biopsy specimens of lymphomas, a new assay was developed using antibodies against active caspase 3 and p89, a protein fragment generated by caspase-specific cleavage of poly-ADP ribose polymerase (PARP). Using this assay, it was found that in B-cell lymphomas, levels of active caspase 3/p89-positive cells correlate strongly with morphologically recognizable apoptotic cells. The number of active caspase 3/p89-positive cells was low in follicular lymphomas and usually high in diffuse large cell lymphomas. Highest numbers were found in Burkitt lymphomas and in two biopsies of diffuse large B-cell lymphomas (DLCLs) obtained several days after initiation of therapy. It is concluded that apoptosis in reactive lymphoid tissues and in B-cell lymphomas always involves activation of effector caspase 3 and cleavage of one of the major effector caspase substrates, PARP-1. Moreover, levels of effector caspase activation are constantly low in low-grade follicular lymphomas and vary considerably in DLCL and Burkitt lymphoma.
MeSH term(s)	Apoptosis ; Biomarkers/analysis ; Burkitt Lymphoma/enzymology ; Burkitt Lymphoma/pathology ; Caspase 3 ; Caspases/analysis ; Enzyme Activation ; Enzyme Precursors/analysis ; Humans ; Immunohistochemistry/methods ; Infectious Mononucleosis/enzymology ; Infectious Mononucleosis/pathology ; Jurkat Cells ; Lymph Nodes/enzymology ; Lymph Nodes/pathology ; Lymphoma, B-Cell/enzymology ; Lymphoma, B-Cell/pathology ; Lymphoma, Follicular/enzymology ; Lymphoma, Follicular/pathology ; Lymphoma, Large B-Cell, Diffuse/enzymology ; Lymphoma, Large B-Cell, Diffuse/pathology ; Poly (ADP-Ribose) Polymerase-1 ; Poly(ADP-ribose) Polymerases ; Proteins/analysis ; Statistics, Nonparametric
Chemical Substances	Biomarkers ; Enzyme Precursors ; Proteins ; PARP1 protein, human (EC 2.4.2.30) ; Poly (ADP-Ribose) Polymerase-1 (EC 2.4.2.30) ; Poly(ADP-ribose) Polymerases (EC 2.4.2.30) ; CASP3 protein, human (EC 3.4.22.-) ; Caspase 3 (EC 3.4.22.-) ; Caspases (EC 3.4.22.-)
Language	English
Publishing date	2002-03
Publishing country	England
Document type	Comparative Study ; Journal Article
ZDB-ID	3119-7
ISSN	1096-9896 ; 0022-3417
ISSN (online)	1096-9896
ISSN	0022-3417
DOI	10.1002/path.1046
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ud II Zs.12: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: High numbers of active caspase 3-positive Reed-Sternberg cells in pretreatment biopsy specimens of patients with Hodgkin disease predict favorable clinical outcome.

Dukers, Danny F / Meijer, Chris J L M / ten Berge, Rosita L / Vos, Wim / Ossenkoppele, Gert J / Oudejans, Joost J

Blood

2002 Volume 100, Issue 1, Page(s) 36–42

Abstract: In vitro studies suggest that resistance to the apoptosis-inducing effect of chemotherapy might explain poor responses to therapy in fatal instances of Hodgkin disease (HD). Execution of apoptosis depends on proper functioning of effector caspases, in ... ...

Abstract	In vitro studies suggest that resistance to the apoptosis-inducing effect of chemotherapy might explain poor responses to therapy in fatal instances of Hodgkin disease (HD). Execution of apoptosis depends on proper functioning of effector caspases, in particular caspase 3, which is activated on the induction of apoptosis through either the stress-induced pathway or the death receptor-mediated pathway. Thus, high levels of caspase 3 activation should reflect proper functioning of one or both identified apoptosis pathways, resulting in chemotherapy-sensitive neoplastic cells and thus a favorable clinical response to chemotherapy. We tested this hypothesis by quantifying active caspase 3-positive tumor cells in primary biopsy specimens of HD and compared these numbers to clinical outcomes. Using an immunohistochemical assay, activation of caspase 3 was detected in 0% to 13% of neoplastic cells. High numbers of active caspase 3-positive tumor cells (5% or more) correlated with excellent clinical prognosis; 0 of 22 patients with 5% or more active caspase 3-positive cells died compared with 11 of 41 patients with less than 5% positive cells (P =.007). Proper functioning of active caspase 3 was demonstrated by the detection of one of its cleaved substrates, PARP-1/p89, in similar percentages of neoplastic cells. High levels of active caspase 3-positive neoplastic cells were associated with the expression of p53 and its downstream effector molecule p21, suggesting proper functioning of the stress-induced apoptosis pathway. In conclusion, high numbers of active caspase 3-positive neoplastic cells predict a highly favorable clinical outcome in HD patients, supporting the notion that an (at least partially) intact apoptosis cascade is essential for the cell killing effect of chemotherapy.
MeSH term(s)	Adolescent ; Adult ; Aged ; Apoptosis ; Biopsy ; Caspase 3 ; Caspases/analysis ; Caspases/metabolism ; Cell Count ; Child ; Female ; Hodgkin Disease/diagnosis ; Hodgkin Disease/enzymology ; Hodgkin Disease/mortality ; Humans ; Male ; Middle Aged ; Poly(ADP-ribose) Polymerases/metabolism ; Prognosis ; Reed-Sternberg Cells/enzymology ; Reed-Sternberg Cells/pathology ; Survival Analysis ; Treatment Outcome ; Tumor Suppressor Protein p53/analysis
Chemical Substances	Tumor Suppressor Protein p53 ; Poly(ADP-ribose) Polymerases (EC 2.4.2.30) ; CASP3 protein, human (EC 3.4.22.-) ; Caspase 3 (EC 3.4.22.-) ; Caspases (EC 3.4.22.-)
Language	English
Publishing date	2002-07-01
Publishing country	United States
Document type	Journal Article
ZDB-ID	80069-7
ISSN	1528-0020 ; 0006-4971
ISSN (online)	1528-0020
ISSN	0006-4971
DOI	10.1182/blood.v100.1.36
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.140: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 364: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma.

ten Berge, Rosita L / Meijer, Chris J L M / Dukers, Danny F / Kummer, J Alain / Bladergroen, Bellinda A / Vos, Wim / Hack, C Erik / Ossenkoppele, Gert J / Oudejans, Joost J

Blood

2002 Volume 99, Issue 12, Page(s) 4540–4546

Abstract: In vitro studies suggest that resistance to chemotherapy-induced apoptosis might explain poor response to therapy in fatal cases. Actual execution of apoptosis depends on proper functioning of effector caspases, particularly caspase 3, and on the ... ...

Abstract	In vitro studies suggest that resistance to chemotherapy-induced apoptosis might explain poor response to therapy in fatal cases. Actual execution of apoptosis depends on proper functioning of effector caspases, particularly caspase 3, and on the expression levels of apoptosis-regulating proteins, including Bcl-2 and the recently identified granzyme B- specific protease inhibitor 9 (PI9). Thus, high levels of caspase 3 activation should reflect proper functioning of the apoptosis pathways, resulting in chemotherapy-sensitive neoplastic cells and a favorable prognosis. We tested this hypothesis by quantifying numbers of tumor cells positive for active caspase 3, Bcl-2, and PI9, respectively, in pretreatment biopsies of systemic anaplastic large cell lymphoma (ALCL) patients and by comparing these numbers with clinical outcome. Activation of caspase 3 in more than 5% of the tumor cells was strongly correlated with a highly favorable outcome. High numbers of Bcl-2- and PI9-positive tumor cells were found to predict unfavorable prognosis. This prognostic effect was strongly related to anaplastic lymphoma kinase (ALK) status: ALK-positive ALCL had significantly higher levels of active caspase 3, while high expression of the antiapoptotic proteins Bcl-2 and PI9 was almost completely restricted to ALK-negative cases. In conclusion, high numbers of active caspase 3-positive tumor cells predict a highly favorable prognosis in systemic ALCL patients. Poor prognosis is strongly related to high numbers of Bcl-2- and PI9-positive neoplastic cells. These data support the notion that a favorable response to chemotherapy depends on an intact apoptosis cascade. Moreover, these data indicate that differences in prognosis between ALK-positive and ALK-negative ALCL might be explained by differences in expression of apoptosis-inhibiting proteins.
MeSH term(s)	Adult ; Anaplastic Lymphoma Kinase ; Apoptosis ; Biomarkers, Tumor/analysis ; Caspase 3 ; Caspases/metabolism ; Female ; Humans ; Lymph Nodes/chemistry ; Lymph Nodes/pathology ; Lymphoma, Large B-Cell, Diffuse/metabolism ; Lymphoma, Large B-Cell, Diffuse/mortality ; Lymphoma, Large B-Cell, Diffuse/pathology ; Male ; Middle Aged ; Poly(ADP-ribose) Polymerases/metabolism ; Prognosis ; Protein-Tyrosine Kinases/metabolism ; Proteins/metabolism ; Proto-Oncogene Proteins c-bcl-2/metabolism ; Receptor Protein-Tyrosine Kinases ; Serpins/metabolism ; Survival Analysis ; Treatment Outcome
Chemical Substances	Biomarkers, Tumor ; Proteins ; Proto-Oncogene Proteins c-bcl-2 ; SERPINB9 protein, human ; Serpins ; Poly(ADP-ribose) Polymerases (EC 2.4.2.30) ; ALK protein, human (EC 2.7.10.1) ; Anaplastic Lymphoma Kinase (EC 2.7.10.1) ; Protein-Tyrosine Kinases (EC 2.7.10.1) ; Receptor Protein-Tyrosine Kinases (EC 2.7.10.1) ; CASP3 protein, human (EC 3.4.22.-) ; Caspase 3 (EC 3.4.22.-) ; Caspases (EC 3.4.22.-)
Language	English
Publishing date	2002-06-15
Publishing country	United States
Document type	Journal Article
ZDB-ID	80069-7
ISSN	1528-0020 ; 0006-4971
ISSN (online)	1528-0020
ISSN	0006-4971
DOI	10.1182/blood.v99.12.4540
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.140: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 364: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?

Bladergroen, Bellinda A / Meijer, Chris J L M / ten Berge, Rosita L / Hack, C Erik / Muris, Jettie J F / Dukers, Danny F / Chott, Andreas / Kazama, Yoshiaki / Oudejans, Joost J / van Berkum, Oskar / Kummer, J Alain

Blood

2002 Volume 99, Issue 1, Page(s) 232–237

Abstract: In tumor cells, the serine protease granzyme B is the primary mediator of apoptosis induced by cytotoxic T lymphocytes (CTLs)/natural killer (NK) cells. The human intracellular serpin proteinase inhibitor 9 (PI9) is the only known human protein able to ... ...

Abstract	In tumor cells, the serine protease granzyme B is the primary mediator of apoptosis induced by cytotoxic T lymphocytes (CTLs)/natural killer (NK) cells. The human intracellular serpin proteinase inhibitor 9 (PI9) is the only known human protein able to inhibit the proteolytic activity of granzyme B. When present in the cytoplasm of T lymphocytes, PI9 is thought to protect CTLs against apoptosis induced by their own misdirected granzyme B. Based on the speculation that tumors may also express PI9 to escape CTL/NK cell surveillance, immunohistochemical studies on the expression of PI9 in various lymphomas were performed. Ninety-two cases of T-cell non-Hodgkin lymphoma (NHL), 75 cases of B-cell NHL, and 57 cases of Hodgkin lymphomas were stained with a PI9-specific monoclonal antibody. In T-cell NHL, highest PI9 expression was found in the extranodal T-cell NHL. In nearly 90% of enteropathy-type T-cell NHLs and 80% of NK/T-cell, nasal-type lymphomas, the majority of the tumor cells expressed PI9. In nodal T-anaplastic large cell lymphomas and peripheral T-cell lymphomas (not otherwise specified), PI9 expression occurred less frequently. In B-cell NHL, PI9 expression was associated with high-grade malignancy; 43% of diffuse large B-cell lymphomas showed PI9(+) tumor cells. Finally, PI9 expression was also found in 10% of Hodgkin lymphomas. This is the first report describing the expression of the granzyme B inhibitor PI9 in human neoplastic cells in vivo. Expression of this inhibitor is yet another mechanism used by tumor cells to escape their elimination by cytotoxic lymphocytes.
MeSH term(s)	Antibodies, Monoclonal ; Apoptosis ; Granzymes ; Histocytochemistry ; Hodgkin Disease/immunology ; Hodgkin Disease/metabolism ; Humans ; Immunohistochemistry ; Killer Cells, Natural/immunology ; Lymphoma, B-Cell/immunology ; Lymphoma, B-Cell/metabolism ; Lymphoma, Non-Hodgkin/immunology ; Lymphoma, Non-Hodgkin/metabolism ; Lymphoma, T-Cell/immunology ; Lymphoma, T-Cell/metabolism ; Serine Endopeptidases/metabolism ; Serpins/analysis ; T-Lymphocytes, Cytotoxic/enzymology ; T-Lymphocytes, Cytotoxic/immunology ; T-Lymphocytes, Cytotoxic/pathology
Chemical Substances	Antibodies, Monoclonal ; SERPINB9 protein, human ; Serpins ; GZMB protein, human (EC 3.4.21.-) ; Granzymes (EC 3.4.21.-) ; Serine Endopeptidases (EC 3.4.21.-)
Language	English
Publishing date	2002-01-01
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	80069-7
ISSN	1528-0020 ; 0006-4971
ISSN (online)	1528-0020
ISSN	0006-4971
DOI	10.1182/blood.v99.1.232
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.140: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 364: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito